SVA Stock Forecast 2025-2026
Distance to SVA Price Targets
SVA Price Momentum
10 Quality Stocks Worth Considering Now
Researching Sinovac (SVA) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on SVA and similar high-potential opportunities.
Latest SVA Stock Price Targets & Analyst Predictions
SVA has shown a year-to-date change of 0.0% and a 1-year change of 0.0%, reflecting flat performance over the past year. Comprehensive analyst forecasts are currently unavailable for SVA. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SVA Analyst Ratings
SVA Price Target Range
Latest SVA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SVA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 20, 2014 | Morgan Stanley | Overweight | Upgrade | $0.00 | |
| Nov 13, 2013 | Aegis Capital | Buy | Maintains | $0.00 | |
| Aug 15, 2013 | Aegis Capital | Buy | Upgrade | $7.00 | |
| May 15, 2013 | Morgan Stanley | Equal-Weight | Upgrade | $3.40 | |
| Mar 14, 2013 | Aegis Capital | Hold | Maintains | $0.00 | |
| Dec 12, 2012 | Aegis Capital | Hold | Initiates | $0.00 |
Sinovac Biotech Ltd. (SVA) Competitors
The following stocks are similar to Sinovac based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Sinovac Biotech Ltd. (SVA) Financial Data
Sinovac Biotech Ltd. has a market capitalization of $642.44M with a P/E ratio of 6.7x. The company generates $448.27M in trailing twelve-month revenue with a 59.5% profit margin.
Revenue growth is +183.6% quarter-over-quarter, while maintaining an operating margin of -33.6% and return on equity of -0.9%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Sinovac Biotech Ltd. (SVA) Business Model
About Sinovac Biotech Ltd.
Biotechnology company specializing in vaccine development.
Sinovac Biotech generates revenue through the research, development, and commercialization of vaccines for various infectious diseases. The company utilizes traditional inactivated virus methodologies to produce its vaccines, allowing for broad accessibility and effectiveness in diverse health systems. Additionally, strategic partnerships and regulatory approvals enable Sinovac to expand its market reach internationally.
Based in Beijing, China, Sinovac gained prominence during the COVID-19 pandemic with the launch of its CoronaVac vaccine. The company's focus on traditional science allows for quick responses to emerging health challenges, positioning it as a significant player in the global healthcare sector.
Sinovac Biotech Ltd. (SVA) Latest News & Analysis
Sinovac Biotech Ltd. (NASDAQ:SVA) received a court order from the Privy Council on February 8, 2025, confirming the rightful election of shareholder nominees from the 2018 AGM.
The court order confirming shareholder election rights may boost Sinovac's governance credibility, potentially enhancing investor confidence and affecting stock performance.
Sinovac Biotech Ltd. announced that the Privy Council in London ruled in favor of a shareholder-nominated board from the 2018 AGM and deemed the company's Rights Agreement invalid.
The Privy Council's ruling validates a shareholder-backed board, potentially altering corporate governance and influencing investor confidence and stock performance in Sinovac.
SINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Against Hand Foot and Mouth Disease (HFMD)
3 months agoSinovac Biotech Ltd. (NASDAQ: SVA) has begun enrollment for a Phase III clinical trial of a vaccine candidate against HFMD, targeting Enterovirus 71 and Coxsackievirus 16, with no approved multivalent vaccines globally.
The initiation of a Phase III trial for a unique HFMD vaccine by Sinovac could position the company as a leader in an unexploited market, potentially boosting stock value and investor interest.
Sinovac Biotech Ltd. reported H1 2024 sales of $121.3 million, down from $140.4 million year-over-year, with a net loss of $10.9 million, or $0.11 per share.
Sinovac's declining sales and net loss highlight potential operational challenges, impacting investor confidence and stock performance. Future growth prospects may be questioned.
SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F
10 months agoSinovac Biotech Ltd. (NASDAQ: SVA) has filed its 2023 annual report with the SEC, detailing unaudited financial results for H2 2023. The report is available on its investor relations website.
Sinovac's annual report filing indicates transparency and regulatory compliance, crucial for investor confidence. Financial results can influence stock performance and investment decisions.
Sinovac Amends Shareholder Rights Plan
1 year agoSinovac Biotech Ltd. (NASDAQ: SVA) has amended its shareholder rights plan, extending its expiration date from February 22, 2024, to February 22, 2025.
The extension of Sinovac's shareholder rights plan signals enhanced shareholder protection, potentially stabilizing stock value and attracting investor confidence amid market uncertainties.
Frequently Asked Questions About SVA Stock
What is Sinovac Biotech Ltd.'s (SVA) stock forecast for 2025?
Based on our analysis of 1 Wall Street analysts, Sinovac Biotech Ltd. (SVA) has a median price target of $3.40. The highest price target is $6.00 and the lowest is $1.50.
Is SVA stock a good investment in 2025?
Analyst ratings for SVA are not currently available. The stock is currently trading at $6.47. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SVA stock?
Wall Street analysts predict SVA stock could reach $3.40 in the next 12 months. This represents a -47.4% decrease from the current price of $6.47. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Sinovac Biotech Ltd.'s business model?
Sinovac Biotech generates revenue through the research, development, and commercialization of vaccines for various infectious diseases. The company utilizes traditional inactivated virus methodologies to produce its vaccines, allowing for broad accessibility and effectiveness in diverse health systems. Additionally, strategic partnerships and regulatory approvals enable Sinovac to expand its market reach internationally.
What is the highest forecasted price for SVA Sinovac Biotech Ltd.?
The highest price target for SVA is $6.00 from at , which represents a -7.3% decrease from the current price of $6.47.
What is the lowest forecasted price for SVA Sinovac Biotech Ltd.?
The lowest price target for SVA is $1.50 from at , which represents a -76.8% decrease from the current price of $6.47.
What is the overall SVA consensus from analysts for Sinovac Biotech Ltd.?
Analyst ratings for SVA are not currently available. The stock is trading at $6.47.
How accurate are SVA stock price projections?
Stock price projections, including those for Sinovac Biotech Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
